

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

---

Claims 1-9 (Canceled)

E1  
Claim 10 (Currently Amended): ~~A~~ An isolated glycoprotein antigen having a molecular weight of 200 kD or more as determined by SDS-PAGE under reducing conditions, which is expressed by cells of human lung adenocarcinoma, and is secreted by said lung adenocarcinoma, wherein said glycoprotein antigen specifically binds to a monoclonal antibody of an IgM isotype produced by a hybridoma selected from the group consisting of FERM BP-5383, FERM P-14879 and FERM P-14880, and wherein said antigen is present on lung adenocarcinoma and not on squamous cell carcinoma, stomach cancer cells, breast cancer cells, and colon cancer cells.

Claim 11 (Currently Amended): ~~The glycoprotein antigen according to Claim 10,~~  
An isolated glycoprotein antigen having a molecular weight of 200 kD or more as determined by SDS-PAGE under reducing conditions, which is expressed by cells of human lung adenocarcinoma, and is secreted by said lung adenocarcinoma, wherein said glycoprotein antigen specifically binds to a monoclonal antibody of an IgM isotype

produced by a hybridoma selected from the group consisting of FERM BP-5383, FERM P-14879 and FERM P-14880, wherein said antigen is present on lung adenocarcinoma and not on squamous cell carcinoma, stomach cancer cells, breast cancer cells, and colon cancer cells and further wherein said glycoprotein antigen reacts with MAA lectin and PNA lectin but does not react with GNA lectin, SNA lectin, and DSA lectin.

61 Claim 12 (Previously Presented): An immunoassay method for diagnosis of human lung adenocarcinoma which comprises contacting a sample suspected of containing human lung adenocarcinoma cells with a diagnostically effective amount of said monoclonal antibody or a fragment thereof of claim 10, and determining whether said sample contains human adenocarcinoma cells based on the binding or absence of binding of the glycoprotein antigen in said sample to said monoclonal antibody.

Claims 13-14 (Canceled)

Claim 15 (Previously Presented): The immunoassay method according to Claim 12, wherein said antibody is a Fab, F(ab)<sub>2</sub> or Fv fragment.

---